Z Squared (ZSQR) Registration filing summary

Company overview and business model

• Operates as a biopharmaceutical and technology company focused on cell therapy platforms for cancer, autoimmune, and infectious diseases, and AI-powered technology solutions for operational efficiency.

• Product pipeline includes CD38-GEAR-NK (gene-edited NK cell therapy), CD38-Diagnostic (companion diagnostic), SNAP-CAR platform (universal CAR cell therapy), and unmodified NK cell therapies.

• Expanded into technology with the acquisition of NexGenAI Affiliates Network, an AI marketing and robotic process automation platform.

• Operates through subsidiaries: SNAP Biosciences Inc. and GEAR Therapeutics Inc. (majority owned), and wholly owned Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., and Coeptis Pharmaceuticals, LLC.

• Pursues growth via portfolio optimization, strategic partnerships, and business development in oncology and technology sectors.

Financial performance and metrics

• Reported net loss of $10.88 million for the year ended December 31, 2024, compared to a net loss of $21.27 million in 2023.

• Accumulated deficit as of December 31, 2024 was $98.23 million.

• Minimal revenue generated to date, primarily from consulting and product sales; significant revenue not expected until product commercialization.

• Cash balance at year-end 2024 was $532,885, down from $1.47 million at year-end 2023.

• Operating expenses decreased to $10.05 million in 2024 from $21.49 million in 2023, mainly due to lower R&D and legal costs.

Use of proceeds and capital allocation

• May receive up to $20 million in gross proceeds from sales of common stock to Yorkville under the Standby Equity Purchase Agreement (SEPA); proceeds to be used for working capital and general corporate purposes.

• No proceeds from the resale of shares by selling stockholders.

• Raised $10 million in Series A Preferred Stock in 2024, with proceeds supporting R&D and subsidiary operations.